pneumonia
common
infect
transplant
infect
highest
mortal
roughli
two
third
pneumonia
observ
hsct
infecti
origin
observ
prioriti
lead
investig
infectionrel
mortal
decreas
hsct
time
sure
incid
pneumonia
decreas
parallel
patient
may
develop
pulmonari
symptom
within
fi
rst
day
allogen
hsct
even
tcelldeplet
allogen
hsct
incid
pneumonia
seem
low
occurr
pneumonia
signifi
cantli
impact
surviv
rate
bacteri
viral
polymicrobi
pneumonia
seem
differ
fi
rst
month
transplant
allogen
autolog
hsct
recipi
rate
invas
fungal
diseas
ifd
much
higher
allogen
hsct
due
sever
prolong
immun
defect
also
favor
late
infecti
complic
factor
enhanc
risk
infecti
pneumonia
mani
includ
donor
recipi
serolog
previou
pneumonia
may
warrant
secondari
prophylaxi
graft
sourc
choic
donor
condit
graftversushost
diseas
gvhd
also
environment
factor
one
main
concern
pneumonia
evalu
distinguish
infecti
noninfecti
pneumonia
sinc
mani
noninfecti
caus
may
mimic
infect
addit
pulmonari
coinfect
frequent
make
result
indirect
marker
even
though
extrem
use
practic
cautious
consid
may
identifi
part
respons
pathogen
direct
investig
lung
provid
bronchoalveolar
lavag
bal
combin
use
wellchosen
indirect
marker
give
best
chanc
identifi
sever
caus
pneumonia
chapter
focus
factor
make
lung
particularli
suscept
infect
hsct
main
specifi
citi
clinic
imag
present
pulmonari
infect
principl
diagnosi
manag
hsct
lung
hsct
candid
may
expos
toxic
insult
underli
diseas
prior
infect
prior
chemotherapi
irradi
may
compromis
normal
surveil
barrier
condit
transplant
subsequ
immunosuppress
therapi
infect
may
impair
nativ
defens
increas
risk
pulmonari
infect
ciliat
squamou
epithelium
nasopharynx
distal
bronchiol
fi
rst
line
defens
signifi
cant
impair
ciliari
epithelium
report
even
year
transplant
respect
role
viral
mycoplasma
infect
gvhd
radiat
fi
nding
precis
determin
howev
abnorm
found
longterm
allogen
hsct
survivor
probabl
underestim
routin
practic
alveolar
macrophag
act
phagocyt
secret
cytokin
chemokin
provid
next
level
defens
function
may
alter
immunosuppress
agent
viral
infect
prolong
neutropen
phase
number
alveolar
macrophag
decreas
could
favor
infect
pathogen
normal
phagocyt
alveolar
level
addit
allogen
hsct
recipi
alveolar
macrophag
progress
replac
cell
donor
origin
may
partli
explain
numer
function
impair
alveolar
macrophag
popul
fi
rst
month
transplant
occurr
infecti
pneumonia
relat
interrelationship
infecti
exposur
reactiv
condit
lung
degre
immunosuppress
chang
mani
transplant
procedur
includ
variou
prophylax
avail
new
diagnost
tool
last
decad
chang
incid
pneumonia
hsct
howev
clear
data
support
hypothesi
one
may
consid
chang
result
chang
time
caus
pneumonia
rather
incid
mortal
increas
use
reduc
intens
condit
ric
regimen
significantli
decreas
formerli
high
rate
earli
bacteri
pneumonia
howev
concomitantli
multidrugresist
mdr
bacteria
becom
global
concern
hematolog
ward
use
ric
also
chang
kinet
mani
complic
delay
onset
gvhd
subsequ
infect
preemptiv
prophylact
strategi
cmv
infect
also
consider
reduc
incid
cmv
pneumonia
nowaday
affect
less
patient
howev
pneumonia
due
respiratori
virus
becom
common
new
antifung
agent
improv
therapeut
option
aspergillu
infect
nonaspergillu
mold
especi
mucormycos
seen
increas
frequenc
final
despit
signifi
cant
progress
morbid
mortal
pneumonia
hsct
remain
one
highest
transplant
time
infecti
pneumonia
follow
time
infect
accord
type
transplant
occurr
sever
gvhd
main
factor
prolong
infecti
risk
neutropen
phase
hsct
recipi
risk
nosocomi
commun
infect
accord
phase
transplant
environment
risk
alway
prevent
contrari
reactiv
risk
must
evalu
transplant
pneumonia
hsct
although
chang
transplant
procedur
impact
infecti
complic
time
see
chap
x
infecti
pneumonia
hsct
occur
predict
risk
period
allogen
transplant
earli
bacteri
pneumonia
mainli
complic
myeloabl
transplant
opportunist
fungal
viral
infect
may
affect
patient
irrespect
type
condit
autolog
transplant
pneumonia
occur
neutropen
phase
especi
myeloma
patient
fungal
origin
bacteri
pneumonia
occur
initi
neutropenia
caus
pathogen
common
neutropen
patient
compar
mucos
ward
clinician
also
consid
possibl
streptococc
pneumonia
ard
relat
streptococc
sepsi
infect
particularli
due
streptococcu
viridan
correl
presenc
mucos
use
prophylact
quinolon
administr
high
dose
cytarabin
see
chap
approach
bacteri
pneumonia
earli
transplant
similar
neutropen
host
includ
coverag
pseudomona
speci
eventu
mdr
case
previou
colon
infect
patient
maintain
indwel
intraven
cathet
throughout
period
seed
lung
bacteremia
continu
potenti
risk
recoveri
neutropenia
allogen
transplant
recipi
continu
risk
nosocomi
infect
long
stay
hospit
see
figur
bacteri
infect
occur
late
posttransplant
period
may
favor
persist
immunoglobulin
defi
cienci
increas
risk
pneumonia
caus
encapsul
bacteria
invas
pneumococc
infect
occur
signifi
cantli
often
allogen
autolog
transplant
especi
case
chronic
gvhd
may
rapidli
fatal
prospect
studi
european
blood
marrow
transplant
group
pneumonia
develop
seven
case
invas
infect
observ
day
wherea
seen
case
observ
day
half
fatal
case
late
infect
associ
pneumonia
earli
immun
conjug
vaccin
complet
polysaccharid
later
fourth
dose
conjufigur
patient
receiv
allogen
hsct
unrel
donor
acut
myeloid
leukemia
smoker
suffer
chronic
bronchiti
transplant
rehospit
month
transplant
sever
chronic
gvhd
treat
steroid
develop
febril
pneumonia
day
hospit
lung
ct
scan
show
groundglass
patchi
infi
ltrate
left
lower
lobe
bronchoalveolar
lavag
posit
coronaviru
cultur
protect
aspir
cfusml
cultur
lavag
fl
uid
cfusml
posit
klebsiella
pneumonia
gate
vaccin
case
gvhd
could
reduc
incid
pneumococc
infect
time
see
chap
similarli
h
infl
uenza
may
caus
pneumonia
sinu
infect
usual
past
third
month
transplant
immun
conjug
vaccin
type
b
recommend
month
transplant
pneumonia
intracellular
pathogen
rare
report
may
recur
previous
expos
patient
pneumonia
due
legionella
speci
occasion
report
set
outbreak
often
nosocomi
infect
radiolog
fi
nding
may
variabl
may
mimic
fungal
nodul
may
appar
onset
high
fever
pleurit
pain
invas
nocardiosi
report
allogen
transplant
mainli
occur
patient
receiv
tmpsmx
often
diffi
cult
differenti
fungal
pneumonia
mycobacteri
infect
due
tuberculosi
mycobacterium
aviumintracellular
complex
speci
rare
report
gener
diagnos
month
transplant
may
develop
earli
prior
infect
occur
see
figur
fungal
pneumonia
aspergillu
worrisom
caus
ifd
allogen
hsct
reportedli
occur
transplant
common
site
lung
gvhd
main
risk
factor
see
chap
x
fi
rst
peak
incid
occur
neutropen
period
myeloabl
condit
regimen
particularli
patient
leukemia
second
incid
peak
gener
seen
later
patient
acut
gvhd
receiv
corticosteroid
avail
antifung
azol
antiaspergillu
prophylaxi
signifi
cantli
reduc
incid
howev
mortal
aspergillu
remain
close
recent
seri
infect
must
consid
case
fever
particularli
occur
patient
broadspectrum
antibiot
pneumonia
whether
new
onset
previous
diagnos
condit
resolv
appropri
therapi
see
figur
neg
bronchoscopi
result
even
combin
test
galactomannan
bal
fl
uid
diminish
suspicion
pathogen
without
secondari
prophylaxi
eventu
combin
surgic
remov
main
lesion
risk
relaps
prior
aspergillu
infect
hsct
estim
around
addit
found
lung
parenchyma
aspergillu
may
isol
tracheobronchi
tree
may
respons
signifi
cant
airway
obstruct
white
adher
plaqu
may
seen
bronchoscopi
particularli
set
chronic
gvhd
steroid
use
infect
must
differenti
worsen
bronchiol
inappropri
danger
increas
immunosuppress
avoid
pneumonia
due
candida
speci
rare
report
partli
fi
rm
criteria
differenti
invas
infect
colon
base
bronchoscopi
without
biopsi
exist
lung
may
involv
system
candida
speci
infect
pneumonia
due
endem
fungi
histoplasma
coccidioid
speci
particularli
north
america
must
consid
patient
emerg
fungi
includ
trichosporon
alternaria
fusarium
special
attent
paid
possibl
mucoral
allogen
hsct
see
chap
mortal
rate
mucormycosi
share
aspergillosi
common
risk
factor
usual
occur
later
often
voriconazol
administr
although
role
select
pressur
debat
indirect
avail
marker
mucormycosi
except
pcr
test
current
evalu
classic
present
mucormycosi
transplant
mostli
mimic
aspergillosi
galactomannan
neg
see
figur
differenti
mucor
aspergillu
infect
howev
great
import
due
differ
therapeut
implic
long
doubt
two
infect
patient
must
treat
liposom
amphotericin
b
pneumocysti
jirovecii
pneumonia
pjp
histor
incid
pjp
patient
receiv
prophylaxi
found
fi
rst
month
transplant
incid
dramat
decreas
use
trimethoprimsulfamethoxazol
tmpsmx
prophylaxi
mortal
establish
pjp
remain
around
woman
receiv
allogen
hsct
hlaident
brother
poorrisk
acut
myeloid
leukemia
past
histori
pulmonari
tuberculosi
year
ago
intoler
secondari
prophylaxi
three
month
transplant
well
gvhd
develop
insidi
fever
chest
xray
normal
lung
ct
scan
show
diffus
micronodular
infi
ltrate
subpariet
nodul
cm
diamet
upper
left
lobe
bronchoalveolar
lavag
posit
tuberculosi
cultur
howev
patient
receiv
dapson
prophylaxi
incid
report
allogen
hsct
pjp
usual
manifest
fever
nonproduct
cough
dyspnea
diffus
interstiti
pneumon
hsct
recipi
present
pjp
may
extrem
abrupt
patient
may
quickli
deterior
requir
intens
care
unit
icu
rare
diseas
may
reveal
isol
lowgrad
fever
normal
chest
xray
begin
case
caus
fever
rapidli
found
ct
scan
show
pulmonari
groundglass
lesion
prompt
bal
elev
ldh
poorli
help
patient
present
nodular
infi
ltrate
pattern
diffus
interstiti
pneumonia
pleural
effus
pneumothorax
uncommon
case
occur
month
transplant
patient
acut
chronic
gvhd
relaps
underli
diseas
receiv
steroid
especi
phase
taper
recent
withdraw
receiv
compliant
tmpsmx
prophylaxi
whether
low
count
main
risk
factor
develop
pjp
hsct
unknown
p
jirovecii
cultiv
vitro
may
identifi
ed
microscop
detect
direct
indirect
immunofl
uoresc
nucleic
acid
test
nat
see
sever
stain
may
use
microscop
detect
trophic
form
cyst
respiratori
sampl
giemsa
identifi
trophic
form
toluidin
blue
calcofl
uor
white
detect
cyst
without
signifi
cant
differ
diagnost
perform
better
sensit
convent
stain
combin
one
classic
stain
allow
detect
cystic
trophic
form
pcr
sensit
diagnost
assay
identifi
pneumocysti
although
studi
defi
ne
clear
cutoff
posit
hsct
recipi
nonhivinfect
patient
known
infect
low
burden
cyst
decreas
gradient
pneumocysti
burden
upper
lower
respiratori
airway
probabl
explain
young
patient
year
old
receiv
allogen
hsct
unrel
donor
acut
lymphoblast
leukemia
second
remiss
got
sever
e
acut
gvhd
compliant
antimold
azol
prophylaxi
develop
acut
right
chest
pain
fever
xray
ct
scan
show
macronodular
isol
lesion
right
lower
lobe
serum
galactomannan
assay
neg
b
bronchoalveolar
lavag
smear
show
hypha
characterist
aspergillu
gomorigrocott
stain
cultur
bal
fl
uid
grew
aspergillu
fumigatu
patient
receiv
allogen
hsct
acut
lymphoblast
leukemia
unrel
donor
got
sever
cutan
gut
gvhd
treat
steroid
month
transplant
still
mgkg
prednison
develop
nodular
lesion
right
lower
lobe
galactomannan
test
posit
serum
refus
fi
broscopi
treat
aspergillu
infect
voriconazol
attend
consult
month
came
back
bilater
thorac
pain
fever
ct
scan
show
bilater
pleural
effus
volumin
round
necrot
lesion
surround
area
consolid
right
lower
lobe
rhizopu
grew
bal
fl
uid
diffi
culti
identifi
p
jirovecii
induc
sputum
upper
respiratori
sampl
convent
techniqu
nonhivinfect
patient
therefor
bal
fl
uid
prefer
specimen
diagnosi
pjp
hsct
recipi
anoth
argument
bal
half
pjp
case
nonhivinfect
patient
associ
coinfect
especi
bacteria
cmv
aspergillu
spp
requir
identifi
cation
treatment
case
bal
done
upper
respiratori
tract
urt
specimen
like
induc
sputum
oral
wash
nasal
swab
nasopharyng
aspir
use
lower
expect
diagnost
valu
bal
serum
beta
glucan
major
cell
wall
compon
p
jirovecii
two
metaanalys
shown
excel
sensit
due
panfung
natur
frequenc
ifd
hsct
screen
tool
pjp
hand
use
bal
fl
uid
recommend
due
poor
sensit
reproduc
recent
guidelin
fi
fth
european
confer
infect
leukemia
propos
practic
algorithm
diagnost
pjp
nonhivinfect
patient
base
examin
bal
fl
uid
qpcr
posit
neg
techniqu
sign
presenc
absenc
pjp
posit
qpcr
neg
refl
ect
technic
problem
mainli
qpcr
qpcr
posit
assay
although
quantit
cutoff
uniformli
propos
high
fungal
burden
favor
diagnosi
pjp
concomit
posit
serum
beta
dglucan
addit
argument
favor
pjp
bal
possibl
patient
hypoxem
refus
procedur
serum
beta
dglucan
help
conjunct
urt
sampl
clinic
suspicion
pjp
high
bal
done
immedi
empir
treatment
tmpsmx
start
soon
possibl
sinc
impair
diagnost
yield
investig
procedur
least
sever
day
tmpsmx
dose
mgkg
tmp
plu
mgkg
smx
oral
prefer
iv
rout
fi
rst
choic
treatment
even
patient
suppos
take
tmpsmx
prophylaxi
presenc
dihydroptero
synthas
mutat
signifi
cantli
affect
treatment
effi
caci
addit
steroid
hypoxem
patient
breath
room
air
mmhg
although
well
establish
hivinfect
patient
debat
other
pjp
prophylaxi
strongli
recommend
engraft
least
month
allogen
hsct
longer
far
immunosuppress
drug
administ
least
month
autolog
hsct
larg
prospect
seri
compar
respect
prophylact
effi
caci
tmpsmx
altern
hsct
recipi
howev
strong
argument
acquir
immunodefi
cienci
syndrom
prospect
studi
hsct
retrospect
seri
suggest
tmpsmx
best
prophylact
regimen
altern
tmpsmxdapson
atovaquon
pentamidineb
inferior
neutropen
phase
transplant
incid
herp
simplex
viru
hsv
reactiv
diseaseinclud
pneumoniaha
fallen
sharpli
wide
use
prophylact
acyclovir
valaciclovir
begin
cmv
signifi
cant
pathogen
pneumonia
allogen
transplant
affect
recipi
preemptiv
prophylact
strategi
greatli
decreas
incid
current
rang
gener
febril
diseas
radiograph
pattern
primarili
interstiti
sometim
alveolar
coinfect
frequent
optim
approach
identifi
viru
lung
combin
rapid
cultur
bal
fl
uid
identifi
cation
cmv
pcr
bal
fl
uid
shown
limit
correl
develop
cmv
pneumonia
therefor
consid
criteria
cmv
pneumonia
see
chap
therefor
laboratori
abandon
assay
autom
qpcr
techniqu
care
examin
bal
smear
experi
cytologist
import
detect
cytolog
hallmark
cmv
pneumonia
know
identifi
cation
characterist
inclus
alveolar
cell
sign
advanc
infect
see
herpesvirus
includ
varicellazost
viru
ebv
human
herpesviru
report
caus
pneumonia
hsct
recipi
high
level
dna
found
lung
tissu
patient
idiopath
cmv
interstiti
pneumon
howev
clinic
signifi
canc
fi
nding
need
specifi
c
therapi
still
unclear
pneumonia
caus
respiratori
virus
becom
main
concern
hsct
recipi
list
regularli
enlarg
main
risk
factor
death
earli
onset
transplant
neutropenia
lymphopenia
gvhd
steroid
administr
older
age
recent
immunodefi
cienci
score
system
propos
predict
poor
outcom
better
identifi
patient
infect
respiratori
syncyti
viru
benefi
antivir
therapi
incid
lower
autolog
allogen
transplant
identifi
cation
nat
respiratori
sampl
recommend
techniqu
may
perform
nasopharyng
throat
swab
bronchial
aspir
bal
fl
uid
multiplex
assay
diagnos
patient
earli
sever
benefi
ts
infect
may
effi
cientli
treat
eg
oseltamivir
infl
uenza
infect
ribavirin
respiratori
syncyti
viru
impli
isol
barrier
measur
prevent
transmiss
patient
staff
respiratori
viral
infect
earli
allogen
transplant
predict
develop
alloimmun
lung
syndrom
includ
bronchiol
obliteran
idiopath
interstiti
pneumonia
respiratori
virus
detect
transplant
delay
transplant
consid
measl
pneumonia
rare
report
hsct
may
expect
event
set
outbreak
may
occur
without
rash
adenoviru
pneumonia
rare
potenti
lifethreaten
event
occur
set
either
dissemin
adenoviru
infect
usual
upper
lower
respiratori
tract
infect
see
chap
occur
frequent
children
adult
unrel
transplant
tcell
deplet
report
pulmonari
toxoplasmosi
rare
usual
seen
set
dissemin
infect
result
reactiv
fi
rst
year
transplant
seroposit
recipi
receiv
tmpsmx
pattern
usual
diffus
interstiti
diseas
neurolog
symptom
may
absent
toxoplasmosi
may
identifi
ed
bal
fl
uid
blood
qpcr
prospect
screen
qpcr
patient
risk
may
allow
preemptiv
therapi
lung
site
numer
noninfecti
injuri
caus
one
third
pulmonari
infi
ltrate
hsct
need
consid
may
requir
specifi
c
treatment
pulmonari
edema
pulmonari
embol
acut
respiratori
distress
syndrom
may
occur
time
often
earli
phase
transplant
without
special
present
transplant
recipi
detail
noninfecti
process
affect
lung
deserv
specifi
c
consider
either
frequent
specifi
calli
observ
hsct
recipi
noninfecti
process
may
associ
infect
increas
diffi
culti
propos
optim
treatment
best
identifi
cation
howev
crucial
import
sinc
steroid
may
indic
sever
noninfecti
process
deleteri
infect
probabl
occurr
may
vari
time
transplant
type
transplant
alveolar
hemorrhag
ah
frequent
noninfecti
process
affect
lung
hsct
incid
rate
ah
diagnos
basi
either
bloodi
aspect
bal
fl
uidusu
transientor
presenc
siderophag
among
alveolar
macrophag
see
figur
ah
hsct
may
autonom
process
favor
thrombocytopenia
coagul
disord
renal
failur
ruptur
alveolarcapillari
barrier
pulmonari
edema
may
also
associ
infect
like
aspergillu
cmv
two
third
case
neither
clinic
present
imag
specifi
c
infecti
noninfecti
form
secondari
alveolar
proteinosi
ap
rare
occur
mostli
prolong
neutropenia
result
complex
process
probabl
combin
pneumocyt
ii
stimul
quantit
function
defect
alveolar
macrophag
result
impair
clearanc
pulmonari
surfact
accumul
lipoproteinac
period
acidschiff
pa
posit
materi
alveolar
space
see
figur
usual
mimic
insidi
pulmonari
edema
diagnosi
may
suspect
sticki
aspect
bal
fl
uid
diffi
culti
count
cell
usual
stain
identifi
ap
cytologist
must
awar
possibl
examin
alveolar
materi
pa
black
sudan
stain
secondari
ap
rare
complic
sever
respiratori
failur
occur
neutropenia
usual
improv
neutrophil
recoveri
howev
ah
case
associ
infect
pulmonari
venoocclus
diseas
rare
event
hsct
mainli
manifest
pulmonari
arteri
hypertens
normal
pulmonari
arteri
occlus
pressur
diagnosi
extrem
diffi
cult
analog
liver
venoocclus
diseas
hypothes
due
chemotherapi
andor
radiat
toxic
small
vessel
engraft
syndrom
may
observ
neutrophil
recoveri
median
onset
day
transplant
usual
associ
follow
criteria
fever
skin
rash
weight
gain
due
capillari
leakag
respiratori
failur
without
identifi
ed
caus
hypothes
degranul
upcom
neutrophil
could
induc
lung
injuri
engraft
syndrom
associ
larg
dose
mononuclear
cell
infus
use
gcsf
gmcsf
earli
neutrophil
recoveri
nonmyeloabl
condit
use
amphotericin
b
therapi
autolog
rather
allogen
transplant
incid
report
children
allogen
myeloabl
transplant
one
fourth
suffer
pulmonari
symptom
sever
patient
may
requir
steroid
import
quickli
rule
infect
idiopath
noninfecti
interstiti
pneumonia
complic
report
allogen
hsct
studi
high
mortal
rate
diagnosi
impli
rule
least
main
infect
classic
present
diffus
interstiti
pneumonia
especi
viral
pneumonia
pjp
cardiac
dysfunct
fl
uid
overload
myeloabl
transplant
associ
leukemia
myelodysplast
syndrom
sever
acut
chronic
gvhd
highdos
total
bodi
irradi
older
age
allogen
hsct
incid
reduc
myeloabl
nonmyeloabl
condit
recent
studi
show
among
hsct
recipi
develop
idiopath
pulmonari
syndrom
seattl
retrospect
microbiolog
screen
bal
materi
bacteria
virus
search
nat
galactomannan
identifi
ed
patient
one
pathogen
mainli
rhinoviru
cmv
aspergillu
fi
nding
associ
increas
mortal
day
confi
rm
rate
idiopath
pneumonia
highli
depend
far
infect
search
bronchiol
obliteran
bo
oblit
bronchiol
import
factor
contribut
death
usual
month
hsct
report
allogen
hsct
condit
relat
older
age
unrel
donor
total
bodi
irradi
decreas
serum
immunoglobulin
g
chronic
gvhd
frequenc
patient
chronic
gvhd
surviv
day
seem
prevent
tcell
deplet
graft
bo
usual
occur
insidi
cough
dyspnea
wheez
may
complic
fever
mimic
bronchopulmonari
infect
hallmark
airway
obstruct
lung
ct
scan
show
hyperinfl
ate
bronchiectasi
mosaic
pattern
bal
endoscop
sampl
limit
valu
aim
rule
infect
noncontributori
bal
defi
nite
rule
infect
prefer
perform
two
consecut
bal
week
interv
increas
chanc
miss
pathogen
often
associ
sinus
complic
infect
especi
caus
haemophilu
infl
uenza
pneumonia
aspergillu
speci
respiratori
virus
despit
immunosuppressor
prognosi
poor
alveolar
nodular
infi
ltrate
may
seen
set
allogen
hsct
result
bronchiol
obliteran
organ
pneumonia
boop
also
call
cryptogen
organ
pneumonia
boop
much
less
common
bo
also
consid
manifest
gvhd
also
report
autolog
hsct
occur
earlier
bo
usual
fi
rst
month
follow
transplant
ct
scan
show
nodular
opac
patchi
consolid
pulmonari
function
test
show
restrict
defect
histolog
diagnosi
strongli
recommend
boop
may
mimic
infect
revers
corticosteroid
therapi
malign
lung
lesion
may
seen
hsct
either
due
primari
secondari
cancer
local
relaps
hematolog
malign
see
figur
ebv
lymphoprolif
diseas
see
chap
x
manag
pneumonia
hsct
requir
high
degre
suspicion
earli
use
diagnost
procedur
increas
avail
indirect
marker
infect
tend
decreas
earli
use
bal
howev
bal
remain
easier
safer
procedur
identifi
infecti
noninfecti
caus
pneumonia
invas
diagnost
procedur
transbronchi
lung
biopsi
need
select
situat
bal
noncontributori
weigh
risk
increas
morbid
systemat
approach
pneumonia
hsct
recipi
includ
consider
follow
histori
clinic
present
imag
knowledg
patient
exposur
travel
environment
risk
previou
document
infect
hospit
epidemiolog
pretranspl
donor
recipi
serolog
particularli
regard
cmv
toxoplasmosi
essenti
histori
recurr
mdr
bacteri
infect
may
requir
special
consider
choos
antibiot
evalu
patient
complianc
antiinfect
prophylaxi
especi
tmpsmx
may
essenti
evalu
risk
pjp
whether
patient
neutropen
lymphopen
hypogammaglobulinem
present
may
import
list
main
infecti
hypothes
symptom
sign
pneumonia
may
may
typic
known
infecti
caus
howev
none
specifi
c
immunosuppress
patient
fi
nding
may
present
symptom
must
care
quickli
evalu
consider
infect
rapidli
progress
fever
cough
sputum
product
may
absent
hypoxemia
may
sole
fi
nding
even
xray
normal
case
chest
ct
scan
obtain
quickli
bronchoscop
evalu
consid
presenc
symptom
may
howev
refl
ect
noninfecti
etiolog
acut
thorac
pain
without
hemoptysi
may
indic
embol
diseas
may
also
denot
aspergillu
infect
pneumothorax
may
revealor
complicatepjp
mycobacteri
aspergillu
infect
fi
brosi
rapid
onset
pneumonia
mainli
consist
bacteri
pneumonia
pjp
pulmonari
edema
hemorrhag
thromboembol
may
also
occur
viral
infect
immunosuppress
patient
subacut
onset
suggest
ifd
although
may
present
abruptli
posttransplant
pneumonia
may
focal
multifoc
diffus
interstiti
alveolar
mix
everi
effort
must
made
quickli
obtain
chest
xray
optim
qualiti
highresolut
chest
ct
scan
easili
avail
xray
supin
posit
rare
help
addit
xray
pattern
nonspecifi
c
mani
patient
mix
type
infi
ltrate
xray
appear
neg
show
minim
chang
good
evid
chest
ct
may
reveal
abnorm
ct
scan
best
neg
predict
valu
rule
pneumonia
show
lung
imag
day
chest
xray
ct
may
addit
provid
local
lesion
guid
invas
procedur
inform
proxim
pulmonari
vessel
inform
also
import
evalu
pneumonia
hematopoiet
stem
cell
transplant
risk
hemoptysi
aspergillosi
ct
may
also
detect
small
pleural
effus
ct
fi
nding
may
suggest
presenc
particular
infect
exampl
halo
signa
macronodul
cm
diamet
surround
perimet
groundglass
opacityi
evoc
earli
aspergillosi
neutropenia
may
also
seen
infect
eg
legionella
mycobacteri
infect
mucormycosi
viral
infect
similarli
revers
halo
sign
atol
sign
focal
groundglass
attenu
surround
ring
consolidationha
shown
often
due
mucormycosi
hematolog
patient
may
also
observ
infect
includ
aspergillosi
groundglass
opac
nonspecifi
c
consist
infecti
mani
noninfecti
process
pulmonari
edema
hemorrhag
howev
even
characterist
lesionssuch
air
crescent
sign
rare
hsct
evoc
mold
infectiona
ct
scan
replac
need
identif
pathogen
diagnosi
magnet
reson
imag
mri
usual
provid
inform
ct
except
detect
lung
abscess
use
pet
scan
limit
diagnosi
acut
pneumonia
may
better
nodular
subacut
lesion
identifi
extrapulmonari
lesion
follow
treatment
effi
caci
workup
use
imag
complet
rapidli
lead
quickli
diagnost
procedur
case
empir
approach
consid
like
hypothes
blood
cultur
perform
routin
limit
valu
diagnos
pneumonia
except
pathogen
high
propens
blood
streptococcu
pneumonia
neutropenia
special
cultur
media
requir
nocardia
atyp
mycobacteria
suspect
blood
also
quickli
sampl
cmv
antigenemia
quantit
realtim
pcr
qpcr
patient
risk
microbi
document
site
infect
skin
biopsi
cerebrospin
fl
uid
may
use
blood
biomark
diagnosi
ifd
includ
detect
galactomannan
enzymelink
immunosorb
assay
beta
glucan
colorimetr
assay
beta
glucan
panfung
marker
galactomannan
mainli
associ
aspergillosi
although
may
posit
mold
infect
eg
fusariosi
metaanalysi
studi
show
galactomannan
test
sensit
specifi
citi
proven
invas
aspergillosi
assay
seem
use
prospect
screen
neutropen
patient
rather
diagnos
pneumonia
also
use
neutropen
nonneutropen
patient
cutoff
posit
usual
recommend
index
plasma
serum
autopsybas
studi
sensit
specifi
citi
serum
beta
glucan
test
detect
ifd
respect
serum
beta
glucan
test
also
use
indirect
diagnosi
pjp
fungal
nat
also
wide
investig
hsct
recipi
consensu
use
clinic
practic
current
exist
time
noninvas
test
replac
specifi
citi
direct
pulmonari
investig
exist
although
sputum
may
analyz
yield
organ
colon
oropharynx
clinic
relev
result
evid
base
set
hsct
posit
cultur
may
valuabl
agent
normal
inhabit
oropharynx
isol
especi
legionella
mycobacteria
fungi
document
mdr
colon
may
guid
empir
antibacteri
treatment
hsct
recipi
pneumonia
posit
sputum
cultur
may
highli
suspici
pulmonari
aspergillosi
similarli
presenc
tuberculosi
sputum
may
consid
caus
pneumonia
clinic
radiolog
sign
support
etiolog
assert
consid
caution
nontubercul
mycobacteria
nasopharyng
aspir
wash
use
detect
respiratori
virus
patient
urt
infect
howev
correl
caus
concomit
pneumonia
presumpt
coinfect
frequent
standard
diagnos
pulmonari
infect
hsct
bronchoscop
sampl
bal
tabl
lavag
safe
minim
invas
reproduc
overal
diagnost
yield
compar
one
lung
biopsi
infecti
diagnost
much
less
complic
clinician
consult
pulmonari
specialist
bal
consid
platelet
transfus
patient
thrombocytopen
alert
microbiolog
laboratori
ensur
potenti
organ
sought
oxygen
satur
arteri
pressur
assess
procedur
fever
transient
hypoxemia
worsen
chest
xray
may
expect
mani
one
half
patient
hour
follow
procedur
patient
hypoxem
mmhg
spontan
supplement
tachypn
bal
usual
benefi
ts
noninvas
ventil
immedi
procedur
overal
diagnost
yield
bal
infecti
pneumonia
occur
hematolog
patient
vari
depend
mani
paramet
follow
local
pulmonari
lesion
whether
access
bal
whether
patient
neutropen
yield
procedur
usual
lower
neutropen
nonneutropen
patient
type
causal
infect
exampl
diagnost
yield
bal
convent
mycolog
techniqueswithout
galactomannan
test
bal
fl
uidfor
aspergillu
pneumonia
usual
lower
higher
pjp
cmv
pneumonia
one
rare
need
lung
biopsi
laboratori
exam
perform
fi
broscop
sampl
laboratori
protocol
establish
advanc
multidisciplinari
approach
accord
expect
infecti
noninfecti
caus
pneumonia
eventu
adapt
season
respiratori
virus
criteria
use
defi
ne
specifi
c
entiti
exampl
gener
believ
presenc
candida
bal
fl
uid
bronchial
aspir
necessari
mean
candida
pneumonia
presenc
aspergillu
hsct
recipi
howev
caus
pneumonia
consensu
defi
nition
increas
avail
nat
mani
pathogen
replac
mani
instanc
classic
techniqu
need
classic
techniqu
shown
longer
use
diagnos
given
infect
delay
elaps
present
bal
number
durat
previou
antibiot
perform
bal
diagnost
yield
bal
shown
better
perform
earli
onset
pulmonari
symptom
seri
hsct
patient
underw
bal
diagnost
yield
procedur
patient
sinc
less
h
versu
other
anoth
studi
diagnost
yield
patient
underw
bal
within
day
present
thereaft
may
due
effect
previou
antiinfect
probabl
identifi
pathogen
also
fact
lung
infl
ammatori
lesion
may
persist
time
transbronchi
biopsi
essenti
noninfecti
process
less
contribut
bal
infecti
pneumonia
howev
usual
propos
initi
investig
pneumonia
due
possibl
complic
pneumothorax
bleed
bcye
buffer
charcoal
yeast
extract
afb
acidfast
bacillu
immunofl
uoresc
pcr
polymeras
chain
reaction
pneumonia
hematopoiet
stem
cell
transplant
infect
control
delay
bal
may
perform
patient
favor
outcom
still
imag
clinic
sign
therefor
recommend
bal
soon
possibl
final
although
pneumonia
less
frequent
autolog
allogen
hsct
diagnost
yield
bal
report
lower
pneumonia
occur
autolog
rather
allogen
hsct
howev
despit
variabl
bal
well
toler
correctli
process
laboratori
repres
best
diagnost
strategi
minimum
complic
also
notic
cytolog
examin
bal
fl
uid
also
document
alveolar
hemorrhag
alveolar
proteinosi
routin
bal
protocol
hsct
recipi
includ
least
total
differenti
cell
count
cytocentrifug
prepar
use
stain
well
cytolog
examin
cell
pellet
obtain
centrifug
cytocentrifug
stain
stain
papanicola
stain
virus
gomorigrocott
method
p
jirovecii
fungi
tabl
stain
necessari
identifi
alveolar
proteinosi
pa
mycobacteria
zielh
siderophag
perl
prussian
blue
sampl
fl
uid
sent
bacteriolog
fungal
cultur
viral
test
galactomannan
detect
may
done
bal
fl
uid
especi
neutropen
patient
aspergillosi
higher
cutoff
serum
aspir
bal
fl
uid
examin
legionella
pneumophila
cultur
eventu
nat
nocardia
mycobacteria
due
better
sensit
qpcr
convent
stain
assay
laboratori
alreadi
use
qpcr
exclus
virus
interest
hsct
patient
virus
herp
famili
adenovirus
respiratori
virus
ie
respiratori
syncyti
viru
infl
uenza
parainfl
uenza
rhinovirus
metapneumovirus
coronavirus
enterovirus
bocaviru
determin
particularli
set
known
exposur
season
outbreak
protect
bacteriolog
sampl
pb
done
protect
brush
specimen
plug
telescop
cathet
process
quantit
cultur
techniqu
although
determin
mechan
ventil
patient
minim
threshold
bacteri
concentr
requir
usual
consid
isol
pathogen
caus
pneumonia
colonyform
unit
cfu
ml
pb
cfusml
bal
fl
uid
due
increas
risk
provid
bleed
pneumothorax
transbronchi
biopsi
routin
acut
pneumonia
occur
patient
hsct
propos
fi
rst
bronchoscopi
bal
also
add
signific
inform
concomit
bal
case
case
noncontributori
bronchoscopi
one
consid
perform
second
bal
andor
transbronchi
biopsi
better
transthorac
needl
aspir
lesion
nodular
subpleur
hsct
focal
lesion
develop
persist
despit
antibiot
mostli
fungal
origin
success
fi
ne
needl
aspir
guid
either
ultrasound
ct
report
complic
rate
around
use
document
ifd
procedur
fail
fi
nal
decis
lung
biopsi
open
videoassist
thoracoscopi
empir
treatment
cover
like
organ
made
transplant
physician
lung
specialist
weigh
risk
surgeri
empir
treatment
failur
reach
diagnosi
etiolog
like
time
transplant
lung
biopsi
help
clinic
cours
prolong
pattern
nodular
cavitari
pneumonia
occur
hsct
may
life
threaten
empir
antibiot
like
organ
must
start
immedi
best
approach
conduct
bronchoscop
investig
bal
soon
possibl
howev
delay
initi
treatment
especi
acut
like
bacteri
pneumonia
present
patient
neutropen
consider
given
likelihood
fungu
patient
prolong
neutropenia
gvhd
steroid
therapi
empir
treatment
may
render
subsequ
test
neg
especi
bacteria
virus
yet
may
warrant
empir
treatment
affect
chanc
isol
pathogen
least
sever
day
empir
treatment
begun
eg
tmpsmx
p
jirovecii
antifung
agent
aspergillosi
daili
clinic
reevalu
perform
especi
diagnosi
initi
establish
patient
improv
use
noninvas
marker
initi
posit
mostli
use
assess
treatment
effi
caci
patient
initi
posit
blood
cultur
sampl
blood
cultur
control
daili
neg
shown
aspergillu
infect
initi
posit
serum
plasma
galactomannan
test
quantit
evolut
test
correl
prognosi
soon
fi
rst
week
therapi
serial
followup
xray
prefer
lung
ct
scan
repeat
accord
type
sever
pneumonia
howev
infect
although
favor
evolv
may
associ
long
persist
imag
abnorm
may
take
sever
month
decreas
disappear
absenc
new
lesion
per
se
reason
reinvestig
patient
clinic
outcom
favor
aspergillosi
shown
transient
increas
volum
fungal
lesion
ct
scan
may
occur
time
neutropenia
recoveri
without
signifi
canc
treatment
failur
new
investig
rapidli
undertaken
pneumonia
respond
empir
treatment
even
caus
pneumonia
ha
establish
occurr
new
infi
ltrate
regard
suspici
treatment
failur
new
infect
associ
success
sever
caus
pneumonia
uncommon
set
bal
initi
done
access
lesion
second
one
consid
result
laboratori
back
except
bal
perform
poor
condit
case
new
lesion
usual
delay
week
fi
rst
noncontributori
bal
second
bal
minim
initi
lesion
peripher
nodular
bal
noncontribut
transthorac
fi
ne
needl
biopsi
consid
lesion
subacut
chronic
respons
target
empir
treatment
surgic
biopsi
may
contempl
chronic
nodular
lesion
pneumonia
caus
icu
transfer
roughli
one
third
case
allogen
autolog
hsct
recipi
although
prognosi
hsct
patient
transfer
icu
slightli
increas
time
decis
transfer
remain
diffi
cult
term
emot
burden
patient
famili
caregiv
use
predict
scoressuch
sepsisrel
organ
failur
assess
sofa
assess
icu
transfer
hsct
recipi
debat
patient
acut
respiratori
failur
benefi
icu
support
investig
bal
know
bal
increas
need
mechan
ventil
prognosi
icu
support
usual
better
autolog
rather
allogen
hsct
recipi
sever
acut
gvhd
corticosteroid
usual
clearli
benefi
icu
support
guidelin
adapt
new
data
gener
clinician
consid
individu
chanc
surviv
return
accept
life
transfer
patient
icu
patient
famili
provid
reason
estim
prognosi
transfer
addit
likelihood
continu
life
support
consid
regularli
cours
treatment
patient
respond
noninvas
mechan
ventil
better
prognosi
requir
mechan
ventil
pneumonia
princip
determin
posttransplant
surviv
predict
time
infect
type
transplant
prophylact
regimen
institut
farreach
benefi
ts
howev
chang
transplant
procedur
condit
immunosuppress
regimen
may
affect
incid
caus
infecti
pneumonia
addit
new
pathogen
emerg
familiar
pathogen
becom
resist
high
level
suspicion
pneumonia
occur
transplant
recipi
vigil
diagnos
treat
continu
requir
prevent
increas
mortal
pneumonia
develop
indirect
diagnost
procedur
essenti
evalu
pneumonia
clinic
pertin
must
establish
larg
prospect
studi
replac
direct
investig
lung
mainli
bal
